Udemy's stock could see a lift from AI-driven content and a focus on enterprise sales. Here's why UDMY stock is a "Buy" after a 20% dip.

A new study has identified a promising drug target for a common chronic illness that could shield insulin-producing cells from a destructive 'identity crisis.' ...